Press Releases

Entegrion, a company focused on products that control bleeding, aims to raise $3.8 million in a third round of financing to fund commercialization of its first approved product: a bandage with a weave of bamboo and glass fibers that promotes clotting.

Richard Martin, CFO of Entegrion, joined forty-four distinguished professionals as Triangle Business Leader and BDO Seidman LLP’s 2009 Top CFO’s of the Triangle. The 2009 Top CFO winners were selected out of 140 nominations from the categories of Financial Services, Infrastructure, Real Estate, Tech & Telecom, Business Services, and Products & Services.

Entegrion, Inc., a privately owned life sciences product development company specializing in technologies for hemorrhage control, resuscitation, and tissue repair, was a winner in the 2009 New Product & Technology Awards.

The U.S. Navy has awarded two additional contracts to the life sciences company Entegrion, Inc., for implementation of the company’s proprietary technologies to improve the safety and availability of blood-derived products for treating combat injuries.  Recent medical research has demonstrated that such blood component therapy is essential in responding to traumatic injury, especially on the battlefield.  The base contracts total about $4 million, with an additional $2 million for expanded research.

Entegrion welcomes Dr. Scott Olitsky back from his successful ascent of Mt. Kilimanjaro. 

In the midst of a difficult economy, the North Carolina Biotechnology Center continues to award grants, this time for projects that bring together university and corporate scientists around the state.

The Stasilon® product has been effective for HHT patients including Dr. Scott Olitsky who as a result will be carrying it on his ascent of Mt. Kilimanjaro in February, 2009.

Late in 2008, Entegrion provided sample kits of Stasilon® to the Hereditary Hemorrhagic Telangiectasia (HHT) Foundation for distribution to its board members and medical advisors.  HHT is an inherited disease that is associated with abnormal blood vessel anatomy leading to internal and external bleeding that can be life threatening.  Nosebleeds are a particular nuisance for these patients since most materials used to stop the bleeding stick to the clot and dislodge it, leading to more bleeding.  In addition, because the clot is not left in place, healing of the vascular network cannot proceed normally.

Chapel Hill, N.C. — When Dr. Thomas Fischer became scientific director of UNC's Francis Owen Blood Research Laboratory, he continued the work of his predecessor, Dr. Marjorie Read, on a product that was ready to begin the U.S. Federal Drug Administration oversight process.

Research Triangle Park, N.C., January 21, 2009 – Life sciences company Entegrion continues to strengthen its leadership team with the addition of Peter C. Johnson, MD, who will serve as Executive Vice President and Chief Business Officer.

Conventional cotton gauze has long been the standard for controlling bleeding, but Entegrion’s Stasilon® dressing will soon change how consumers care for wounds. Entegrion has just announced that LC Industries of Durham, N.C., will handle consumer sales of Stasilon® - FR through its secure online ordering system.

Dr. Thomas Fischer, the vice president and chief science officer at Entegrion, is scheduled to speak at the National Hemophilia Foundation’s 60th Annual Meeting, in Denver, CO.

Entegrion announced today that it has been awarded a contract from the Department of the Navy for the development of an integrated dried blood plasma storage and administration prototype.

 Research Triangle Park, N.C., development company specializing in technologies for hemorrhage control, resuscitation,and tissue repair, announced that it has received 510(k) market approval from the U. S.Food and Drug Administration (FDA) for its hemostatic medical textile technology.

 Research Triangle Park, N.C., innovation through collaboration. When Dr. Thomas Fischer first developed the notion ofa hemostatic textile that integrated glass fibers, Entegrion turned to leaders in the N.C. textile industry to produce the unique weave.

“New haemostatic textile stopped refractory bleeding in an aplastic anaemia patient”  Research Triangle Park, N.C.,

Stasilon™ - FR wound dressing will be showcased at the Council for EntrepreneurialDevelopment’s 2008 Biotech Conference, held May 19-20 at the Benton ConventionCenter in Winston Salem. Presenting the recently FDA approved Stasilon™ .

 Entegrion, joins twenty-four distinguished professionals as magazine’ were chosen from more than 180 nominations, and are recognized for their notableachievements and contributions to the Triangle business community.

Research Triangle Park, N.C., July 8, 2008 – Life sciences company Entegrion continues to strengthen its leadership team with the addition of Michael Galiger, its newmanufacturing and engineering manager.